HEART FAILURE

Questions will come up about how to treat “DIASTOLIC” heart failure...or heart failure with a PRESERVED ejection fraction (HFpEF). Over HALF of heart failure patients have this type, which is due to a stiff left ventricle that can’t adequately fill. This is different from “SYSTOLIC” heart failure...or heart failure with a REDUCED ejection fraction (HFrEF). These patients have a weak left ventricle that can’t pump effectively.

There’s less evidence for how to treat heart failure with a preserved ejection fraction...so the meds used may be different. ACEIs or ARBs might reduce hospitalizations, but don’t seem to decrease mortality...like they do in reduced ejection fraction HF. Beta-blockers don’t seem to reduce mortality either.

Recommend treating hypertension. Most patients with preserved ejection fraction HF have high BP...and BP control may slow progression. Suggest BP meds based on the patient’s other conditions, such as an ACEI or ARB for kidney disease...or a beta-blocker or amlodipine for angina. It’s also okay to suggest a thiazide diuretic.

But expect to see less use of loop diuretics (furosemide, etc) in preserved ejection fraction HF. Loops may be needed for fluid overload, but overdoing it may worsen symptoms.

If these measures aren’t enough, don’t be surprised to see spironolactone added. Early evidence suggests it may be helpful for preserved ejection fraction HF...but hyperkalemia is common.

Don’t recommend Entresto (sacubitril/valsartan) or Corlanor (ivabradine). It’s too soon to say if they improve outcomes in this case. Help manage other comorbidities that can aggravate heart failure symptoms...atrial fibrillation, COPD, obesity, sleep apnea, etc.

See our toolbox, Improving Heart Failure Care, for patient education tools, monitoring tips, and more about treatment options.

(For more on this topic, see Clinical Resource #330409 at PharmacistsLetter.com.)

Discussion Questions

Overview of current therapy
1. What is known about treating heart failure with preserved ejection fraction?

Analysis of new study
2. What type of study was this? How were the patients selected for inclusion?

3. How were the study groups defined?

4. How were the outcomes evaluated?
5. What were the outcomes of this post hoc analysis?

6. What were the strengths and weaknesses of this study?

7. Were the results expressed in terms we care about and can use?

How should the new findings change current therapy?

8. Do the results change your practice? How?

Apply the new findings to the following case

F.M. is a 67-year-old female who presented to the ED with shortness of breath and O₂ sats of 84% on room air. F.M.’s chest x-ray showed bilateral pulmonary edema and pulmonary vascular congestion, and her BNP was elevated at 814 pg/mL. The rest of her bloodwork was normal. Her EKG shows left ventricular hypertrophy. F.M. was admitted for an acute HF exacerbation, or acute decompensated HF.
You find F.M. resting comfortably on 3L O₂ via nasal cannula with sats of 96%. You note that she has a history of hypertension, diabetes, and osteoarthritis with a current BP of 176/93 mmHg and a heart rate of 82. Her current medication list includes lisinopril 40mg daily, chlorthalidone 50mg daily, metformin 1000mg twice daily, pioglitazone 15mg daily, and naproxen 500mg twice daily.

F.M. tells you her dyspnea has been gradually worsening over the last two weeks. She has become more short of breath when walking up stairs and wakes up at night gasping for air. Last night, she could not lay flat without becoming short of breath, which prompted her to come to the ER. She also states that she’s had increased swelling in her legs over the last week, but she attributed it to the warmer weather. Her physical exam is notable for bilateral pulmonary crackles at the bases and 2+ pitting edema bilaterally.

9. What should you recommend for initial treatment of F.M.’s acute heart failure exacerbation?

F.M. is doing well after two days of IV furosemide. She no longer needs supplemental oxygen and is ready to go home. Ischemic heart disease was ruled out, but F.M.’s echocardiogram showed left ventricular hypertrophy and an ejection fraction of 60%. She wants to know if she can do anything in the future to prevent this from happening again. Upon review of her medications, you note that her BP has been persistently elevated on her home regimen despite multiple doses of PRN hydralazine during her admission.

10. How do you counsel F.M. upon discharge about her new diagnosis of heart failure with preserved ejection fraction? What medication adjustments should you consider?

F.M. returns to the clinic for hospital follow-up. Her BP is well-controlled on her new regimen of lisinopril 40mg daily, chlorthalidone 50mg daily, and amlodipine 10mg daily. She was discussing her new heart failure diagnosis at her weekly bridge club and a fellow member mentioned she also had heart failure. They were comparing medication lists and she noticed that her friend is taking 3 medications that she has not been prescribed: carvedilol 6.25mg twice daily, sacubitril/valsartan 49/51mg twice daily, and spironolactone 25mg daily. F.M. asks if she should be on any of these medications.

11. How should you respond to F.M.? Are there other medications that you should consider adding?


---

**Additional Pharmacist’s Letter Resources** available at PharmacistsLetter.com
Welcome to PL Journal Club

PL Journal Club gives you insights and guides you to the discoveries that Pharmacist’s Letter researchers and editors uncover. Each month we analyze many new studies and help you discover the answers to the hard questions. “What are the real advantages and disadvantages of new therapies?” “How do they compare with other options?” “What do pharmacists and prescribers need to know?” We look beyond the headlines and promotional materials to interpret the clinical studies and data. Sometimes the marketing spin doesn’t stand up to scrutiny. Sometimes studies do not really prove what they are reported to prove. PL Journal Club helps you to the truth and how to apply new findings to patient care.

PL Journal Club builds on Pharmacist’s Letter to provide you with background for your own journal club discussions. We won’t bring up every possible question, but you can…in your own group meetings. If a question comes up, go to PharmacistsLetter.com to find more background. As a PL Journal Club participant, you get access to all of Pharmacist’s Letter. Feel free to call or email us with suggestions or if we can be of assistance... 209-472-2240 or PLJournalClub@Pharmacist'sLetter.com.

Instructions

Go to PharmacistsLetter.com to get the PL Journal Club PARTICIPANT NOTES. Use the search function to look for “Journal Club.” You’ll also get great background materials, including Pharmacist’s Letter and clinical resources. PL Journal Club functions like a typical group meeting, except that it is organized for you with the expert analysis of important new studies done by the large Pharmacist’s Letter research and editorial staff. Let the questions serve as a springboard for your discussions. Use our patient cases or your own cases to shape the discussion. Each month, PL Journal Club reviews a topic that is also covered in Pharmacist’s Letter. You’ll also find a library of previous PL Journal Clubs online for your use.

PL Journal Club Contributing Editors:

Lori Dickerson, PharmD, FCCP, Editor; Jennifer Nieman, PharmD, BCPS, Assistant Editor; Lisa D. Mims, MD, Department of Family Medicine, Medical Univ of Southern Carolina, Charleston, SC; Maribeth Porter, MD, Department of Community Health and Family Medicine, Univ of Florida, Gainesville, FL.

Editors and Authors:

Jeff Jellin, PharmD, Editor-in-Chief; Sherri Boehringer, PharmD, BCPS, Senior Editor, VP Content; Karen Davidson, PharmD, Senior Editor; Tammie Armeni, RPh, PharmD, Editor, Director of Continuing Education; Melissa Blair, PharmD, FASHP, FCCP, BCPS; Sandye Chabot, PharmD; Lori Dickerson, PharmD, FCCP, Rachel Maynard, PharmD; Kimberly Palacioz, PharmD, Editors; Stacy Hester, RPh, BCPS; Tanveer Khan, PharmD, Crystal Marie, BSc Pharm, MBA, ACP; Associate Editors; Bethany Bryant, PharmD, BCPS; Vickie Danaher, PharmD; Flora Harp, PharmD; Tanner Higginbotham, PharmD; Jennifer Nieman, PharmD, BCPS; Brea Rowan, PharmD, BCPS; James Van, BSc Pharm; Don Weinberger, PharmD; Marlea Wellein, PharmD, BCPS; Assistant Editors; Karen Wilson, BA, PharmD, MParam, Minda Paglinawan, BA, Assistant Manuscript Editor; Jenni Mangrum, BS, CPhT, Assistant Education and Accreditation Editor, Mark Graber, MD, MSHCE, FACEP, Associate Clinical Editor. Consultants: Jill Allen, PharmD, BCPS; Melanie Cupp, PharmD, BCPS; Katie Lacaria, BSc Pharm, ACP; Heidi Liston, BSc Pharm, PharmD; Lu-An Murdoch, BSc Pharm; Annette Murray, BSc Pharm; Neeta O’Mara, PharmD, BCPS; Jennifer Pennington, RN, BSN. Editorial Advisors: Christophe Anslinger, PA-C; Thomas Barringer, MD, FAAFP; Christopher Barry, PA-C, MMSc; William Bednar, MD, Larissa Bossaer, PharmD, BCPS; Robert Brownwe, MD, FAAFP; Stephen Brunton, MD; Holley Bush, PharmD; Peter Carek, MD, MS; Gary Choy, PharmD; Matthew Cline, MD; John Connolly, MD, FACP, FCCP; Sandra Counts, PharmD; Hikmat Fikrat, PhD; Rex Force, PharmD, FCCP, BCPS; Lawrence Frank, MD, FACP; Peter Garbeff, MD; Mark Garofoli, PharmD, MBA, CGP; Charles Green, RPh; Susan Halasi, MSc Pharm; John Hambright, PharmD; Roland Hart, MD; Kyle Herbold, MD; Patricia Hatton, MD, Sydney Hendry, MD; Raissa Hill, DO; Jerry Jones, MD; Sheela Kapre, MD, FACCP, FCP; Adam Kaye, PharmD, FACP, FCPhA; William Kehoe, PharmD, MA, FCCP, BCPS; Joshua Lenchus, DO, RPh, FACP, SFHM; Stanley Leong, PharmD; Kevin Maeda, PharmD; Christine Marsh, RPh; Eric Matheson, MD, MS; Christina McLaughlin, CPhT EMT; Kay Niegel, RPh; Mike Pattrick, RPh; Ernest Pieper, PharmD; Daren Primack, MD, FCCP; Barbara Rankin, MD; Jenna Reel, PharmD, BCPS, CPE, CDE; George Rishwain, MD; Sandy Robertson, PharmD; Edward Rogan, PharmD, BCACP, Gerald Rubley, MSN, PharmD; Ruth Ruffle, PharmD; AnnieMarie Santos, MD; David Schneider, MD; Allen Shaunessy, PharmD, MMEd; Jonathan Szkotak, PharmD, BCACP, Joshua Tessler, DO; Bruce Uch, PharmD; John David Williamson, MD, FAAFP; Raymond Wong, MD; William Yee, PharmD, FASHP, FSCP; Kent Yei, RPh.

Advisory Board:

Evan Balland, PharmD, Williams Family Medical Ctr; Melvin Baron, PharmD, FMA, Univ of Southern Calif; Jan Basil, MD, FCCP, Medical Univ of South Carolina; Robert Bickerton, MD, FACP; Reid B. Blackwelder, MD, FAAFP, East Tennessee State Univ; Kevin Brown, MD, FACOG, Texas A&M; R. Keith Campbell, RPh, FAADE, FASHP, FAPA, CDE, Washington State Univ; Andrea Darby-Stewart, MD, HonorHealth; Anthony A. Donato, Jr., MD, MHPE, Reading Health System; Jan Drutz, MD, Baylor College of Med; Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FANP, CS, FSAAN, DCC, Fitzgerald Health Ed Associates; Barry Gidal, PharmD, RPh, Univ of Wisc; Martin Grajower, MD, FACP, FACE, Albert Einstein College of Med; B. Joseph Guglielmo, PharmD, UC San Francisco; Stuart Haines, PharmD, BCPS, BCACP, BC-ADM, FCP, FASHP, FAPhA, Univ of Miss; Jeffrey Harman, Jr, MD, UCLA, MC, MS, FACP; Mark Jessen, MD, MPH, FACP; Eric Jackson, PharmD, BCPS, PCAC, Conn; Peter Jacobsen, PhD, DUS, Univ of the Pacific; Paul Jensen, MD, PharmD, FACP; Alan David Kaye, MD, PhD, DABA, DABPM, DABBPH, Louisiana State Univ; Steve Kayser, PharmD, UC San Francisco; Daniel Kessler, DO, FACOFP, Lincoln-Memorial Univ; Edgar Lerma, MD, FACP, FASN, FAHA, Univ of Illinois at Chicago; Evan L. Lipkis, MD; Mark McConnell, MD, Oscar G. Johnson VA Medical Ctr; Stephen L. McKernan, BSc Pharm, ND, DO, FAAFP, Sam Houston State Univ; Steven E. Nissen, MD, MACC, Cleveland Clinic; Brenden O’Hara, RPh, BCACP, Blue Cross/Blue Shield of NC; Douglas S. Pauu, MD, MACP, Univ of Washington; Dan Perri, BSc Pharm, MD, FRCPC, McMaster Univ; Charles Ponte, BS, PharmD, FAADE, FAPA, FASHP, FCCP, FAPhA, West Virginia Schools of Pharmacy & Medicine; David E. Rosenthal, MD, FACP; Joseph S. Scherer, MD, MPH, Eisenhower Medical Ctr; Arthur Shinn, PharmD, FASCP, Managed Pharmacy Consultants; Kelly Anne Spratt, DO, FACCP, Univ of Pennsylvania; Dan Steiber, RPh, Genesis Pharma Consultants; Tom Vicker, PharmD, OPTION Care; C. Wayne Weart, PharmD, FAPhA, FASHP, BCPS, Medical Univ of South Carolina; Craig D. Williams, PharmD, FNLA, BCPS, Oregon Health & Science Univ.

DISCLOSURE:

The editors of this activity and its publisher, Therapeutic Research Center, have no relevant financial interests related to the products or services covered by this activity. Therapeutic Research Center/Pharmacist's Letter does not receive any commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. Pharmacist’s Letter focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers.

Unbiased Evidence and Recommendations for the Pharmacist on New Developments in Drug Therapy

3120 West March Lane, Stockton, CA 95219
TEL (209) 472-2240 – FAX (209) 472-2249
PharmacistsLetter.com

The contents are copyrighted. © 2017 Therapeutic Research Center. All Rights Reserved.